Effective October 8, 2019, Nikhil Mehta, Ph.D., senior vice president of regulatory and quality assurance of AVEO Pharmaceuticals, Inc. (the “Company”), will step down as an officer of the Company to pursue another opportunity. Michael Needle, M.D., chief medical officer, and Emile Farhan, Ph.D., senior vice president of CMC and quality, will lead the efforts to complete the preparation of a potential tivozanib New Drug Application for advanced renal cell carcinoma. Drs. Needle and Farhan successfully led the Company’s efforts to prepare the marketing authorization application (“MAA”) supporting EUSA’s 2016 MAA submission to the European Medicines Agency, which resulted in the approval of tivozanib in 2017 as a treatment for first line advanced renal cell carcinoma in that agency’s covered territories.